Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals

Journal of Viral Hepatitis

Volumn 25, Issue 7, 2018, Pages 870-873

  Schutz A ^a   Moser, S ^b   Schwanke, C ^a   Schubert, R ^a   Luhn, J ^a   Gutic, E ^b   Lang, T ^b   Schleicher, M ^b   Haltmayer, H ^a   Gschwantler, M ^b,c  

^a Suchthilfe Wien gGmbH   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c SIGMUND FREUD UNIVERSITY   (Austria)

Author keywords

directly observed therapy; hepatitis C; ledipasvir; people who inject drugs (PWID); sofosbuvir

Indexed keywords

BUPRENORPHINE; LEDIPASVIR PLUS SOFOSBUVIR; LEVOMETHADONE; METHADONE; MORPHINE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MISCELLANEOUS NAMED GROUPS; NURSE; PATIENT COMPLIANCE; PEOPLE WHO INJECT DRUG; PHYSICIAN; PRIORITY JOURNAL; REINFECTION; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; ADOLESCENT; AGED; CLASSIFICATION; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; SUBSTANCE ABUSE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DIRECTLY OBSERVED THERAPY; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SOFOSBUVIR; SUBSTANCE ABUSE, INTRAVENOUS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85048962744     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12857     Document Type: Article

References (8)

1. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-583.
2. Behara R, Reau N. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Current Opin Gastroenterol. 2017;33:115-119.
3. WHO. Global health sector strategy on viral hepatitis, 2016-2021. WHO/HIV/2016.06. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1. Accessed August 13, 2017.
4. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63:364-369.
5. Dore GJ, Altice F, Litwin AH, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy. Ann Intern Med. 2016;165:625-634.
6. Schütz A, Moser S, Marchart K, Haltmayer H, Gschwantler M. Direct observed therapy of chronic hepatitis C with interferon-free all-oral regimens at a low-threshold drug treatment facility – a new concept for treatment of patients with borderline compliance receiving opioid substitution therapy. Am J Gastroenterol. 2016;111:903-905.
7. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343-350.
8. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-1888.